Acute kidney injury in patients with malignancy: clinical characteristics, etiology and outcomes across KDIGO stages
DOI:
https://doi.org/10.18203/2349-3933.ijam20262828Keywords:
Acute kidney injury, KDIGO, MalignancyAbstract
Background: Acute kidney injury (AKI) is a frequent and serious complication in patients with malignancy, contributing to increased morbidity, mortality and adverse renal outcomes. This study evaluated the clinical profile, primary etiologies, laboratory characteristics and outcomes of oncology patients with AKI according to kidney disease. Improving global outcomes (KDIGO) staging.
Methods: This retrospective observational study included 100 adult oncology patients with KDIGO-defined AKI admitted between May 2021 and April 2026. Patients were classified as KDIGO stage 1 (n=30), stage 2 (n=35) or stage 3 (n=35). Demographic characteristics, comorbidities, primary etiologies, laboratory parameters and clinical outcomes were compared across AKI stages.
Results: Increasing AKI severity was associated with older age and a higher prevalence of diabetes mellitus, hypertension and hematological malignancies. Sepsis was the most common primary etiology of AKI across all stages. Progressive worsening of hematological, inflammatory, metabolic and biochemical parameters was observed with increasing KDIGO stage (all p<0.001). Complete renal recovery at discharge declined significantly from 83.3% in stage 1 to 20.0% in stage 3, while in-hospital mortality increased from 10.0% to 51.4% (p=0.001). Among hospital survivors, complete recovery at 3 months decreased from 88.9% to 29.4%, whereas progression to chronic kidney disease increased from 7.4% to 52.9% across stages 1 to 3 (both p<0.001). Hospital readmission was more frequent in patients with severe AKI (p=0.048).
Conclusions: Higher KDIGO stage is associated with greater clinical and biochemical derangement, reduced renal recovery, increased CKD progression and higher mortality in oncology patients with AKI. Early recognition and timely intervention may improve renal and patient outcomes in this high-risk population.
References
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138.
Singer M, Deutschman CS, Seymour CW. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801-10.
Evans L, Rhodes A, Alhazzani W. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-247.
Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 2011;22(4):399-406.
Campbell GA, Hu D, Okusa MD. Acute kidney injury in the cancer patient. Adv Chronic Kidney Dis. 2014;21(1):64-71.
Benoit DD, Hoste EA. Acute kidney injury in critically ill patients with cancer. Crit Care Clin. 2010;26(1):151-79.
Soares M, Salluh JI, Carvalho MS, Darmon M, Rocco JR, Spector N. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol. 2006;24(24):4003-10.
Lupușoru M, Lupușoru G, Ailincăi I, Frățilă G, Andronesi A, Micu E, et al. Renal replacement therapy in cancer patients with acute kidney injury (Review). Exp Ther Med. 2021;22(2):864.
Canet E, Zafrani L, Lambert J, Thieblemont C, Galicier L, Schnell D, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013;8(2):55870.
Darmon M, Vincent F, Canet E, Mokart D, Pène F, Kouatchet A, et al. Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie. Nephrol Dial Transplant. 2015;30(12):2006-13.
Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019;38(3):295-308.
Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, et al. Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study. J Natl Cancer Inst. 2019;111(7):727-36.
Braet P, Re Sartò GV, Pirovano M. Treatment of acute kidney injury in cancer patients. Clin Kidney J. 2022;15(5):873-84.
Gupta S, Gudsoorkar P, Jhaveri KD. Acute kidney injury in critically ill patients with cancer. Clin J Am Soc Nephrol. 2022;17(9):1385-98.
Can W, Rong L, Lixia L. Incidence and risk factors of acute kidney injury in patients with malignant tumors: a systematic review and meta-analysis. BMC Cancer. 2023;23:1123.
Calças Marques R. Severe acute kidney injury in hospitalized cancer patients. Cancers (Basel). 2024;16(3):561.
Nazzal Z. The rate and risk factors of acute kidney injury among cancer patients' admissions in Palestine: a single-center study. Int J Nephrol. 2022;2:2972275.
Małyszko J, Kozłowska K, Kozłowski L. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017;32(6):924-36.
Sawinski D. The kidney effects of hematopoietic stem cell transplantation. Adv Chronic Kidney Dis. 2014;21(1):96-105.
Singh N, McNeely J, Parikh S, Bhinder A, Rovin BH, Shidham G. Kidney complications of hematopoietic stem cell transplantation. Am J Kidney Dis. 2013;61(5):809-21.
Abudayyeh A, Wanchoo R. Kidney Disease Following Hematopoietic Stem Cell Transplantation. Adv Chronic Kidney Dis. 2022;29(2):103-115.e1.
Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58-66.
Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53(6):961-73.
Forni LG, Darmon M, Ostermann M, Oudemans-van Straaten HM, Pettila V, Prowle JR, et al. Renal recovery after acute kidney injury. Intensive Care Med. 2017;43(6):855-66.
Macedo E, Mehta RL. Renal recovery after acute kidney injury. Contrib Nephrol. 2016;187:24-35.
Kellum JA. How can we define recovery after acute kidney injury? Considerations from epidemiology and clinical trial design. Nephron Clin Pract. 2014;127(1-4):81-8.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767-78.
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-1854.
Puri I, Sharma D, Gunturu KS, Ahmed AA. Diagnosis and management of tumor lysis syndrome. J Community Hosp Intern Med Perspect. 2020;10(3):269-272.
Perissinotti AJ, Bishop MR, Bubalo J, Geyer MB, Goodrich A, Howard SC, et al. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: results of a modified Delphi panel. Cancer Treat Rev. 2023;120:102603.
Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578-86.
Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115-24.
Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15-25.
Tang C. Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol. 2023;19(1):53-72.
Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do. Kidney Int. 2020;97(1):62-74.
Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review. Kidney Int Rep. 2017;2(1):108-23.
Izzedine H, Perazella MA. Anticancer drug-induced acute kidney injury. Kidney Int Rep. 2017;2(4):504-14.
Downloads
Published
How to Cite
Issue
Section
